7,753 Shares in Insulet Co. (NASDAQ:PODD) Bought by Trilogy Capital Inc.

Trilogy Capital Inc. purchased a new position in Insulet Co. (NASDAQ:PODD) during the fourth quarter, Holdings Channel reports. The firm purchased 7,753 shares of the medical instruments supplier’s stock, valued at approximately $2,024,000.

A number of other hedge funds also recently modified their holdings of the stock. Baillie Gifford & Co. grew its position in Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares during the last quarter. Mizuho Securities USA LLC grew its position in Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after acquiring an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after acquiring an additional 193,839 shares during the last quarter. Westfield Capital Management Co. LP grew its position in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after acquiring an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in Insulet in the third quarter valued at about $16,342,000.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent research reports. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Wells Fargo & Company lifted their price target on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $277.13.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Trading Up 1.0 %

Shares of PODD stock opened at $287.67 on Friday. The company has a market cap of $20.18 billion, a P/E ratio of 49.26, a PEG ratio of 3.49 and a beta of 1.23. The stock has a 50 day simple moving average of $269.95 and a two-hundred day simple moving average of $240.32. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $288.05.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The business had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the previous year, the company posted $0.71 earnings per share. Research analysts forecast that Insulet Co. will post 3.22 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.